Peptide finder

What are you trying to change?

Pick as many as you like. The number on each one is how many people it has been measured in across the whole archive. So you can see where the evidence is before you choose.

1. 01MethotrexateSmall moleculeStrong. At least two finished studies in people, and at least 1,000 people who took it. 2 completed trials, 5,022 people given it.4 reported

   5,022 people2 studies1 found nothing

   • found nothingLow-dose methotrexate did not prevent heart attacks or strokes in people who already had heart disease, and it did not lower the inflammation markers it was supposed to. 4,786 people took it or a dummy pill for about two years, and all took folate too. This is the trial that separates methotrexate from the...

     The New England Journal of Medicine, 2019 · 4,786 people

   • A year of methotrexate given before rheumatoid arthritis was diagnosed did not stop the arthritis from arriving. 236 adults with joint pain took part. They also got one steroid shot at the start. They did have less pain, stiffness and joint inflammation two years on. One region, and an early test of the idea.

     The Lancet, 2022 · 236 people

2. 02ResveratrolSupplementModerate. At least one finished study in people, and at least 100 people who took it. 14 completed trials, 403 people given it.7 reported

   203 people2 studies1 found nothing

   • found nothingThe longest and largest diabetes trial of resveratrol found nothing that counted. 192 patients took 40 mg, 500 mg or a dummy pill every day for six months. An inflammation marker fell further on resveratrol, but not by enough to call real. Weight, waist, blood pressure, blood sugar, insulin and a string of other...

     Pharmacological Research, 2016 · 192 people

   • This is the strongest good human result resveratrol has, and it rests on eleven men. Obese but otherwise healthy men took 150 mg a day for a month, and also spent a month on a dummy pill. Their resting metabolism slowed the way it does when people eat less. Liver fat, blood sugar, triglycerides, a liver enzyme and...

     Cell Metabolism, 2011 · 11 people

3. 03SomatropinBiologicLimited. People have taken it in a published study, but fewer than 100 of them. 2 completed trials, 84 people given it.9 reported

   60 people1 study

   • Take growth hormone away from adults who need it and most things get worse. 60 adults with a pituitary shortage, treated for about ten years, were switched onto a dummy for four months. Their IGF-1 fell sharply. Two aspects of quality of life declined. Waists grew, deep belly fat rose, and cholesterol and an...

     Journal of Clinical Endocrinology and Metabolism, 2012 · 60 people

4. 04ThymalinPeptideModerate. At least one finished study in people, and at least 100 people who took it. 4 completed trials, 308 people given it.7 reported

   42 people1 study

   • A small early-pandemic trial reported faster recovery, and nobody died in either group. 42 patients got thymalin injections into the muscle for five days on top of standard care, and 50 got standard care alone, at one hospital in mid 2020. Lung scans worsened in 2 of the 42 treated against 5 of the 50 controls....

     Stem Cell Reviews and Reports, 2021 · 42 people

5. 05MIB-626SupplementModerate. At least one finished study in people, and at least 100 people who took it. 4 completed trials, 107 people given it.1 reported

   42 people1 study1 found nothing

   • found nothingThe tablet raised NAD in very sick patients and made no difference to them. 42 adults in hospital with COVID-19 and sudden kidney injury took MIB-626 or dummy tablets twice a day for two weeks. NAD in the blood roughly doubled by the end. Kidney blood tests came out the same in both groups. So did inflammation markers...

     FASEB BioAdvances, 2025 · 42 people

6. 06BrimapitidePeptideModerate. At least one finished study in people, and at least 100 people who took it. 4 completed trials, 510 people given it.

   20 people1 study

   • A small safety study in inflamed eyes, with nothing to compare it against. Twenty people who had inflammation inside the eye after surgery or injury got one injection under the surface of the eye. Seventeen side effects were recorded and all were judged unrelated to the drug. Almost none of the peptide reached the...

     Journal of Ocular Pharmacology and Therapeutics, 2015 · 20 people

7. 07BPC-157PeptideLimited. People have taken it in a published study, but fewer than 100 of them. 3 completed trials, 31 people given it.10 reported

   number of people not given1 study

   • A company registered a study of a BPC-157 gummy, marked it completed, and has posted no results. 40 physically active adults were to take two gummies a day for eight weeks, 500 mcg of BPC-157 per serving. The main measurements were two blood markers of inflammation, hs-CRP and IL-6. Everybody was to get the gummy....

     ClinicalTrials.gov, Parlay Wellness, 2025 · number of people not given

8. 08Metformin plus rapamycinSmall moleculePreliminary. Studied in people, but no published study has had people take it. 2 registered with no result.2 reported

   number of people not given1 study

   • The one trial testing this pair cannot tell the two drugs apart. 30 people are enrolled by AgelessRx, an online company that prescribes these drugs, and it is no longer signing people up. Every group stacks rapamycin and metformin together with low-dose naltrexone, NAD+ up the nose, glutathione on the skin and a...

     ClinicalTrials.gov, 2025 · number of people not given

9. 09GDF15BiologicModerate. At least one finished study in people, and at least 100 people who took it. 2 completed trials, 313 people given it.3 reported

   53,902 people2 studies

   • GDF15 tracks with getting sick in general, not with any one disease. Researchers measured thousands of blood proteins in 53,026 UK adults and followed them for over 13 years. Higher GDF15 went with later diagnosis of more than twenty different long-term illnesses, and with having several at once. Much of the level was...

     Metabolism, 2025 · 53,026 people

   • Higher GDF15 marked out men who died sooner, but nobody was given anything. 876 Swedish men aged 35 to 80 gave a blood sample and were then followed for up to 14 years. Those with more GDF15 at the start were roughly three times as likely to die of any cause. The pattern held in a separate set of 324 twins. This is a...

     Aging Cell, 2010 · 876 people

10. 10KPVPeptideAnimal or lab only. Only animal or lab studies on this page. No study in people yet. 2 animal studies, no human study.6 reported

    number of people not given0 studies

    • In mice with colitis, KPV carried in tiny particles sped up healing of the gut lining and lowered a swelling signal called TNF-alpha.

      Molecular Therapy, 2017 · number of people not given

11. 11ThymulinPeptideAnimal or lab only. Only animal or lab studies on this page. No study in people yet. 1 animal study, no human study.1 reported

    number of people not given0 studies

    • In rats. A thymulin copy called PAT cut pain and swelling caused by a bacterial toxin, more so at higher doses.

      British Journal of Pharmacology, 2002 · number of people not given

12. 12KLOW blendBlendLimited. People have taken it in a published study, but fewer than 100 of them. 1 completed trial, 13 people given it.11 reported

    number of people not given0 studies

    • In mice with gut inflammation. KPV given alone led to faster recovery, more weight regained and less inflammation in the colon. Nothing here tests KPV in a mix or in people.

      Inflammatory Bowel Diseases, 2008 · number of people not given

13. 13ChonlutenPeptideAnimal or lab only. Only animal or lab studies on this page. No study in people yet. 2 lab studies, no human study.2 reported

    number of people not given0 studies

    • In a dish. In human immune cells, it cut the release of an inflammation signal after the cells met a bacterial toxin. The study was run with the institute that makes it, so it is not independent.

      International Journal of Molecular Sciences, 2022 · number of people not given

14. 14Ac-SDKPPeptideAnimal or lab only. Only animal or lab studies on this page. No study in people yet. 1 animal study, no human study.2 reported

    number of people not given0 studies

    • In rats. It cut inflammation after brain injury.

      Journal of Neurosurgery, 2017 · number of people not given

15. 15OSK Partial ReprogrammingBiologicPreliminary. Studied in people, but no published study has had people take it. 1 registered with no result.5 reported

    number of people not given0 studies

    • In normally ageing mice, not ones bred to age fast, long stretches of partial reprogramming changed the kidney and skin. The longer the treatment ran, the bigger the change. Ageing clocks read younger. Genes for inflammation, worn-out cells and stress were turned down. The authors did not claim these mice lived longer.

      Nature Aging, 2022 · number of people not given

16. 16E5 Plasma FractionProcedureAnimal or lab only. Only animal or lab studies on this page. No study in people yet. 4 animal studies, no human study.4 reported

    number of people not given0 studies

    • In rats, a fraction of young pig plasma made old organs look much younger on paper. The team first built and checked six tissue-age clocks for rat tissue, from 613 samples. Two of those also work in human tissue. After treatment, the tissue age of blood, heart and liver more than halved. A control centre in the brain...

      GeroScience, 2024 · number of people not given

17. 17ClusterinBiologicPreliminary. Studied in people, but no published study has had people take it. 2 human studies where nobody was given it, 1 registered with no result.4 reported

    number of people not given0 studies

    • In mice, with one human measurement inside it. Plasma from mice that chose to run, given to mice that did not, quietened inflammation genes in the brain. Protein screening showed a rise in a set of immune system brakes, clusterin among them. Clusterin injected into a vein stuck to the lining of brain blood vessels and...

      Nature, 2021 · number of people not given

18. 1825-HydroxycholesterolSmall moleculePreliminary. Studied in people, but no published study has had people take it. 1 human study where nobody was given it.2 reported

    number of people not given0 studies

    • In mice. In mice with clogged arteries, 25-hydroxycholesterol made by immune cells made artery swelling and damage worse. It was also measured in human artery tissue, but only measured. This is a harm result in the same part of the body as the artery stiffness study.

      Circulation, 2023 · number of people not given

19. 19RisuteganibPeptideModerate. At least one finished study in people, and at least 100 people who took it. 2 completed trials, 263 people given it.

    number of people not given0 studies

    • In a dish. Retina support cells were made with mitochondria from 5 people with AMD and 3 without. They were treated with each drug for 48 hours at doses like those used in the eye. The AMD cells showed more signs of cell death at the start. The two drugs changed cell death, stress and swelling genes in different ways....

      Experimental Eye Research, 2021 · number of people not given

20. 2017-alpha-estradiolHormoneAnimal or lab only. Only animal or lab studies on this page. No study in people yet. 4 animal studies, no human study.4 reported

    number of people not given0 studies

    • In mice, this study asked why these drugs mostly help males. It found that the drop in brain inflammation was itself different between males and females. That is part of an answer, not the whole answer.

      Aging Cell, 2017 · number of people not given

21. 21LamivudineSmall moleculeLimited. People have taken it in a published study, but fewer than 100 of them. 1 completed trial, none stating how many people.3 reported

    number of people not given0 studies

    • In mice and in a dish. This is the paper that started the idea. In worn-out cells, jumping genes woke up and set off an immune alarm through loose DNA copies. Drugs that block the copying stopped it. Giving lamivudine to old mice turned down the alarm and cut inflammation in several body parts. It measured...

      Nature, 2019 · number of people not given

22. 22RuxolitinibSmall moleculeModerate. At least one finished study in people, and at least 100 people who took it. 1 completed trial, 309 people given it.

    number of people not given0 studies

    • In human cells in a dish and in old mice. Blocking the JAK pathway quieted the inflammatory signals from zombie cells. In old mice, 10 weeks of a JAK-blocking drug cut inflammation and helped them move better. There is no result in people.

      Proceedings of the National Academy of Sciences, 2015 · number of people not given

23. 23CartalaxPeptideAnimal or lab only. Only animal or lab studies on this page. No study in people yet. 4 lab studies, no human study.8 reported

    number of people not given0 studies

    • In a dish. Aging cartilage cells gave off more aging and inflammation signals. Both Cartalax and a cartilage extract pushed those signals back toward normal. These were cells, not joints, and nobody measured a real health result.

      Advances in Gerontology, 2023 · number of people not given

24. 24ApelinPeptideLimited. People have taken it in a published study, but fewer than 100 of them. 3 completed trials, 68 people given it.3 reported

    number of people not given0 studies

    • Mostly in mice. Mice missing apelin or its receptor lost a lot of muscle with age. Giving apelin signals back improved their muscle. A human part only watched people. In older people, muscle made less apelin with age, and more apelin went with more benefit from exercise. Nobody was given apelin. Public money paid for...

      Nature Medicine, 2018 · number of people not given

1. 01Thymalin with epitalonBlendStrong. At least two finished studies in people, and at least 1,000 people who took it. 2 completed trials, 1,106 people given it.7 reported

   1,106 people1 study1 found nothing

   • found nothingA defined thymus peptide was put through a modern study, and it failed. Just over a thousand people seriously ill with sepsis got either thymosin alpha-1 or a dummy shot, and nobody involved knew which. A month later, the same share had died in each group. It is on this page as a contrast. When a thymus peptide is...

     BMJ, 2025 · 1,106 people

2. 02ThymopentinPeptideModerate. At least one finished study in people, and at least 100 people who took it. 3 completed trials, 306 people given it.3 reported

   206 people2 studies1 found nothing

   • found nothingIt was tested properly for preventing infections after cancer surgery and it did not work. Two hundred and six patients were split by chance around the time of their operation. Infections happened slightly less often on thymopentin, and the gap was small enough that chance explains it. Infections were no less severe...

     British Journal of Surgery, 1994 · 206 people

   • People kept more of a key immune cell, and that is all this shows. Adults with HIV who had no symptoms were given thymopentin or a dummy injection for about six months, and nobody involved knew which. Those on the drug held on to a higher share of CD4 cells, the cells HIV destroys. That is a blood marker, not how...

     AIDS, 1992 · number of people not given

3. 03LeptinBiologicModerate. At least one finished study in people, and at least 100 people who took it. 6 completed trials, 844 people given it.5 reported

   3 people1 study

   • Give leptin to the rare children who have none and it transforms them. Three children born unable to make leptin were injected daily for up to four years. Appetite fell, fat mass fell, insulin and blood fats came back towards normal, and puberty arrived at the right age. Immune cells that had been depleted recovered...

     Journal of Clinical Investigation, 2002 · 3 people

4. 04Dimethyl fumarateSmall moleculeLimited. People have taken it in a published study, but fewer than 100 of them. 3 completed trials, 54 people given it.4 reported

   number of people not given2 studies

   • In relapsing multiple sclerosis, dimethyl fumarate roughly halved the relapse rate over two years compared with a dummy pill, and slowed disability. 27% and 26% on the two doses had a relapse, against 46% on the dummy pill. This is the trial behind the approval. Flushing, gut problems and lower lymphocyte counts were...

     The New England Journal of Medicine, 2012 · number of people not given

   • The second approval trial, with an injected drug, glatiramer, as well as a dummy pill for comparison. Dimethyl fumarate cut relapses compared with the dummy pill, and so did glatiramer. Neither clearly slowed disability. It was not built to say which drug is better.

     The New England Journal of Medicine, 2012 · number of people not given

5. 05ThymalinPeptideModerate. At least one finished study in people, and at least 100 people who took it. 4 completed trials, 308 people given it.7 reported

   number of people not given1 study

   • A small Russian trial about timing the dose, not about whether the drug works. Women of reproductive age with long-running inflammation of the tubes and ovaries were given thymalin, timed to their own immune cells' activity. Improvement in symptoms, blood tests and immune measures was more common when the drug was...

     Bulletin of Experimental Biology and Medicine, 2015 · number of people not given

6. 06EverolimusSmall moleculeStrong. At least two finished studies in people, and at least 1,000 people who took it. 3 completed trials, 1,024 people given it.

   number of people not given1 study

   • The follow up was larger and the result held. Older adults took a low dose combination of two mTOR blocking drugs for six weeks. They reported fewer infections over the following year and their immune response improved. This is the strongest positive result the programme produced. The large trial that came next did...

     Science Translational Medicine, 2018 · number of people not given

7. 07VilonPeptideAnimal or lab only. Only animal or lab studies on this page. No study in people yet. 1 animal study, 1 lab study, no human study.6 reported

   number of people not given0 studies

   • In a dish. In human and rat thymus cells, Vilon pushed young immune cells to mature.

     Bulletin of Experimental Biology and Medicine, 2013 · number of people not given

8. 08BronchogenPeptideAnimal or lab only. Only animal or lab studies on this page. No study in people yet. 2 lab studies, no human study.4 reported

   number of people not given0 studies

   • In a test tube. Bronchogen made DNA from calf and mouse cells a little harder to pull apart. That is a chemistry result, not a lung effect. Like the rest of this peptide's research, it comes from one research group. The paper lists the building blocks in a different order from the one sellers use.

     Bulletin of Experimental Biology and Medicine, 2011 · number of people not given

9. 09DT2216Small moleculeLimited. People have taken it in a published study, but fewer than 100 of them. 1 completed trial, 20 people given it.3 reported

   number of people not given0 studies

   • In mice and in a dish. DT2216 worked against a type of lymph cancer that needs BCL-xL. That adds to the lab case for destroying the protein instead of just blocking it.

     Journal of Hematology and Oncology, 2020 · number of people not given

10. 10ISRIBSmall moleculeAnimal or lab only. Only animal or lab studies on this page. No study in people yet. 3 animal studies, 1 lab study, no human study.4 reported

    number of people not given0 studies

    • In mice. This is the only ageing result. In old mice, ISRIB undid memory loss for places and improved short-term memory. In the memory part of the brain, nerve cells worked more like young ones and regrew contact points. Signs of immune activity in the brain went down. It measured memory, not lifespan. Several authors...

      eLife, 2020 · number of people not given

11. 11Senolytic vaccine (anti-GPNMB)BiologicAnimal or lab only. Only animal or lab studies on this page. No study in people yet. 3 animal studies, no human study.

    number of people not given0 studies

    • In mice. A different team built a tiny-particle vaccine against GPNMB. Given as a shot under the skin, it switched on killer immune cells that cleared zombie fat and heart cells in fast-ageing mice on a high-fat diet. Fat handling and heart function improved. A second team got a similar result, still in mice.

      Human Vaccines and Immunotherapeutics, 2025 · number of people not given

12. 12CerebrolysinPeptideStrong. At least two finished studies in people, and at least 1,000 people who took it. 3 completed trials, 1,591 people given it.8 reported

    number of people not given0 studies
13. 13Thymosin Alpha-1PeptideStrong. At least two finished studies in people, and at least 1,000 people who took it. 2 completed trials, 1,204 people given it.7 reported

    number of people not given0 studies
14. 14Thymosin alpha-1 with KPV and LL-37BlendStrong. At least two finished studies in people, and at least 1,000 people who took it. 3 completed trials, 1,140 people given it.6 reported

    number of people not given0 studies

1. 01SeleniumSupplementModerate. At least one finished study in people, and at least 100 people who took it. 1 completed trial, 35,533 people given it.1 reported

   35,533 people1 study

   • Selenium did not prevent prostate cancer. A huge trial gave men selenium, vitamin E, both, or a dummy pill. None of it lowered prostate cancer. The claim that sold the bottles failed when it was tested at scale.

     JAMA, 2009 · 35,533 people

2. 02Vitamin DSupplementStrong. At least two finished studies in people, and at least 1,000 people who took it. 2 completed trials, 25,871 people given it.4 reported

   25,871 people1 study

   • Vitamin D was tested properly, at scale, and it did not prevent cancer or heart disease. Nearly 26,000 adults were split by chance to take a daily vitamin D pill or a dummy pill. They were followed for more than five years. Neither of the two questions the trial was built to answer came out ahead. Most of these people...

     New England Journal of Medicine, 2019 · 25,871 people

3. 03InsulinPeptideStrong. At least two finished studies in people, and at least 1,000 people who took it. 5 completed trials, 29,691 people given it.4 reported

   12,537 people1 study

   • Giving long-acting insulin early did not protect the heart, and it did not cause cancer either. 12,537 people with heart risk factors and blood sugar problems got insulin glargine or usual care, then were followed for about six years. Heart outcomes came out the same. Blood sugar dropping dangerously low was about...

     New England Journal of Medicine, 2012 · 12,537 people

4. 04AlbiglutideBiologicStrong. At least two finished studies in people, and at least 1,000 people who took it. 2 completed trials, 10,304 people given it.

   9,463 people1 study

   • Albiglutide cut heart attacks, strokes and cardiac deaths in people with diabetes and heart disease. Nearly ten thousand adults across 28 countries were split by chance between the drug and a dummy injection, and followed for about a year and a half. Nobody involved knew which. Seven in a hundred on the drug had a...

     Lancet, 2018 · 9,463 people

5. 05Green tea extractSupplementModerate. At least one finished study in people, and at least 100 people who took it. 1 completed trial, 1,075 people given it.4 reported

   1,075 people1 study

   • A year of high dose green tea extract harmed the liver in a small but real share of women. 1,075 women past menopause took an extract with 843 mg of EGCG a day, or a dummy pill, for one year. Liver enzymes rose in 36 women on the extract against 4 on the dummy pill. Just over 1% had a liver problem serious enough to...

     Food and Chemical Toxicology, 2015 · 1,075 people

6. 06EGCGSupplementStrong. At least two finished studies in people, and at least 1,000 people who took it. 3 completed trials, 1,172 people given it.5 reported

   1,075 people1 study

   • Green tea extract damaged some livers, at ten times the dummy group's rate. 1,075 women past menopause took an extract delivering 843 mg of EGCG a day, or a dummy, for a year. A liver enzyme rose in 36 women on the extract, 6.7 percent, against 4 on the dummy, 0.7 percent. 1.3 percent had a liver problem recorded as...

     Food and Chemical Toxicology, 2015 · 1,075 people

7. 07BPTESSmall moleculeModerate. At least one finished study in people, and at least 100 people who took it. 2 completed trials, 513 people given it.1 reported

   513 people2 studies

   • The only proper test of blocking this enzyme in people found nothing. 444 adults with advanced kidney cancer got telaglenastat plus the cancer drug cabozantinib, or a dummy pill plus cabozantinib. Both groups went about 9.2 and 9.3 months before their cancer grew again. That is the same result twice. Telaglenastat is...

     JAMA Oncology, 2022 · 444 people

   • A smaller study leaned toward the drug without settling anything. 69 adults with advanced kidney cancer got telaglenastat or a dummy pill, both along with the cancer drug everolimus. Two got the drug for every one on the dummy pill. Cancer took 3.8 months to grow again on the drug, against 1.9 months. The bar for...

     Clinical Cancer Research, 2022 · 69 people

8. 08TelaglenastatSmall moleculeModerate. At least one finished study in people, and at least 100 people who took it. 3 completed trials, 513 people given it.1 reported

   513 people2 studies1 found nothing

   • found nothingTelaglenastat was tested properly in a large study, and it did not work. 444 adults with advanced kidney cancer took telaglenastat or a dummy pill, both along with the cancer drug cabozantinib. The cancer grew again after 9.2 months on the drug and 9.3 months on the dummy pill. Tumours shrank in 31 percent against 28...

     JAMA Oncology, 2022 · 444 people

   • A second, smaller study hinted at a benefit and proved nothing. 69 adults with advanced kidney cancer, most already through three treatments, got telaglenastat or a dummy pill, both along with the cancer drug everolimus. Two got the drug for every one on the dummy pill. The cancer grew again after 3.8 months against...

     Clinical Cancer Research, 2022 · 69 people

9. 09TrametinibSmall moleculeStrong. At least two finished studies in people, and at least 1,000 people who took it. 2 completed trials, 1,192 people given it.

   322 people1 study

   • In advanced melanoma with a BRAF mutation, trametinib on its own held the cancer back longer than chemotherapy and more people were alive at six months. Rash, diarrhoea and swelling were the common side effects. This is the trial that led to its approval as a single drug.

     The New England Journal of Medicine, 2012 · 322 people

10. 10GDF15BiologicModerate. At least one finished study in people, and at least 100 people who took it. 2 completed trials, 313 people given it.3 reported

    187 people1 study

    • Blocking GDF15 put weight back on people with cancer who were wasting away. 187 patients with cancer wasting and high GDF15 were put into four groups. Three got the antibody at rising doses. One got a dummy shot. Shots came every four weeks, three times. By twelve weeks the drug groups had gained about 1.2 to 2.8...

      New England Journal of Medicine, 2024 · 187 people

11. 11SulforaphaneSupplementModerate. At least one finished study in people, and at least 100 people who took it. 7 completed trials, 423 people given it.6 reported

    170 people1 study

    • Only the strongest dose did anything, and what it shifted was a chemical in urine. 170 adults in a polluted part of China were split by chance to a dummy drink or one of three strengths of broccoli sprout beverage, for 10 days. The top dose raised benzene clearance by 63.2 percent. The half dose and the fifth dose...

      American Journal of Clinical Nutrition, 2019 · 170 people

12. 12EnobosarmSmall moleculeModerate. At least one finished study in people, and at least 100 people who took it. 1 completed trial, 159 people given it.5 reported

    159 people1 study1 found nothing

    • found nothingMuscle did grow, in people who were losing it to cancer. 159 patients who had already lost weight took one of two doses of enobosarm or a dummy pill for up to about four months. Muscle mass rose on both doses, by roughly 1 to 1.5 kg, while the dummy group did not change. Here is the limit. Growing muscle is not the...

      The Lancet Oncology, 2013 · 159 people

13. 13LandogrozumabBiologicModerate. At least one finished study in people, and at least 100 people who took it. 3 completed trials, 726 people given it.

    125 people1 study

    • In people with pancreatic cancer, the antibody did not help and the treated groups did worse. 125 patients on chemotherapy were split by chance between two doses of the drug and a dummy injection. Those on the dummy lived about ten and a half months. On the lower dose it was just under ten months, and on the higher...

      ClinicalTrials.gov, 2015 · 125 people

14. 14NavitoclaxSmall moleculeModerate. At least one finished study in people, and at least 100 people who took it. 2 completed trials, 137 people given it.2 reported

    46 people1 study

    • Navitoclax on its own barely touched advanced ovarian cancer. 46 women whose cancer no longer responded to chemo took it, with no comparison group, after a median of four earlier treatments. One woman's tumour shrank. 15 saw theirs hold steady. Half were back to growing cancer within about seven weeks. In 12 of the...

      Gynecologic Oncology, 2022 · 46 people

15. 15Angiotensin-(1-7)PeptideLimited. People have taken it in a published study, but fewer than 100 of them. 5 completed trials, 76 people given it.3 reported

    38 people2 studies

    • Given alone to people with an advanced cancer, it did not change the course of the disease. 20 people with sarcoma that had spread got a daily shot under the skin. Their cancer held off for about 2.7 months on average and they lived about 10.2 months. Two people with blood vessel tumours stayed stable far longer. A...

      Sarcoma, 2016 · 20 people

    • The first test in people was about safety, and it turned up serious harm at the top dose. 18 adults with advanced cancer got the peptide as a shot under the skin, daily for five days, with the dose raised group by group. At the highest dose one person had a severe stroke and another lost nerve function in the head,...

      Clinical Cancer Research, 2009 · 18 people

16. 16IO102-IO103PeptideModerate. At least one finished study in people, and at least 100 people who took it. 3 completed trials, 470 people given it.3 reported

    number of people not given1 study

    • This trial was stopped because the vaccine did not do what it was meant to. Seventeen people with head and neck cancer had enrolled. The sponsor recorded the reason for stopping as the study failing to hit its target. A university hospital ran it, not the maker. No results have been published. The record shows a trial...

      ClinicalTrials.gov, Cliniques universitaires Saint-Luc, 2020 · number of people not given

17. 17LanreotidePeptideLimited. People have taken it in a published study, but fewer than 100 of them. 1 completed trial, none stating how many people.4 reported

    number of people not given1 study

    • Lanreotide slowed these tumours down, and that is a rare thing for a peptide to prove. 204 adults with advanced neuroendocrine tumours were split by chance. Half had a lanreotide shot every 28 days for up to two years. Half had a dummy shot, and nobody involved knew which. At two years, 65% of the lanreotide group...

      New England Journal of Medicine, 2014 · number of people not given

18. 18Zinc-L-carnosineSupplementLimited. People have taken it in a published study, but fewer than 100 of them. 1 completed trial, none stating how many people.2 reported

    number of people not given1 study

    • Zinc-L-carnosine cut swallowing trouble in women having radiotherapy after breast cancer surgery. People were assigned to groups by chance, and the trial reported that the supplement prevented the painful swallowing radiation can cause. This is a very short report, and the journal record has no summary, so neither the...

      The Breast Journal, 2020 · number of people not given

19. 19MecaserminPeptideLimited. People have taken it in a published study, but fewer than 100 of them. 1 completed trial, 76 people given it.6 reported

    199,698 people1 study

    • Men with naturally higher IGF-1 in their blood get prostate cancer somewhat more often. Nearly 200,000 men were followed for about seven years. 5,402 were diagnosed with prostate cancer and 295 died of it. The higher a man's level, the higher his risk, and a genetic analysis pointed the same way, which makes a real...

      International Journal of Cancer, 2021 · 199,698 people

20. 20MetforminSmall moleculeModerate. At least one finished study in people, and at least 100 people who took it. 3 completed trials, 489 people given it.6 reported

    3,234 people1 study

    • The longest follow-up in people we have found no drop in deaths. 3234 adults at high risk of diabetes were given metformin, an intensive lifestyle program, or a dummy pill. After a median 21 years, 453 had died. Neither metformin nor lifestyle cut deaths from any cause, cancer or heart disease. Preventing diabetes and...

      Diabetes Care, 2021 · 3,234 people

21. 21RuxolitinibSmall moleculeModerate. At least one finished study in people, and at least 100 people who took it. 1 completed trial, 309 people given it.

    number of people not given1 study

    • Five years on, the same cancer trial still favours the drug. Spleen shrinkage lasted a median of just over three years. People started on ruxolitinib lived longer than those started on the dummy pill, even though most of the dummy group switched onto the drug part way through. Tiredness and diarrhoea were the common...

      Journal of Hematology and Oncology, 2017 · number of people not given

22. 22GW0742Small moleculeAnimal or lab only. Only animal or lab studies on this page. No study in people yet. 3 animal studies, 1 lab study, no human study.3 reported

    number of people not given0 studies

    • In mice given a chemical that causes bowel cancer. GW0742 reduced the cancer, working in a different way from drugs that block the COX2 enzyme. This is mouse work, and it points against the family's cancer worry.

      Carcinogenesis, 2008 · number of people not given

    • found nothingIn a dish and in mice. Neither GW0742 nor GW501516 made five kinds of human cancer cells grow faster, and tissue from treated mice showed no change in these growth markers either. This argues against the idea that this drug family feeds tumours.

      Carcinogenesis, 2007 · number of people not given

23. 23DT2216Small moleculeLimited. People have taken it in a published study, but fewer than 100 of them. 1 completed trial, 20 people given it.3 reported

    number of people not given0 studies

    • In mice and in a dish. DT2216 was gentler on platelets than navitoclax in a dish, and stronger against cancer cells that need BCL-xL. It slowed human tumours grown in mice without a big platelet drop. It was designed this way because platelets have little of the cell tool it uses.

      Nature Medicine, 2019 · number of people not given

    • In mice and in a dish. DT2216 worked against a type of lymph cancer that needs BCL-xL. That adds to the lab case for destroying the protein instead of just blocking it.

      Journal of Hematology and Oncology, 2020 · number of people not given

24. 24OSKM Cyclic Partial ReprogrammingBiologicAnimal or lab only. Only animal or lab studies on this page. No study in people yet. 6 animal studies, no human study.5 reported

    number of people not given0 studies

    • In mice, from the Yamada and Yamanaka labs. Switching the reprogramming genes on and then taking the doxycycline switch away caused tumours in several tissues. The tumour cells were unformed and abnormal, with big changes to the chemical tags across their DNA. The kidney tumours looked like Wilms tumour, a childhood...

      Cell, 2014 · number of people not given